What is Biomodels?
Headquartered in Boston, Biomodels operates as a sophisticated Contract Research Organization (CRO) that provides high-fidelity preclinical research services to a diverse clientele, ranging from emerging biotech startups to established global pharmaceutical entities. The firm distinguishes itself through a deep expertise in complex disease models, specifically targeting inflammatory and immune-mediated conditions, oncology supportive care, and fibrotic diseases. By integrating in vitro, ex vivo, and surgical research methodologies, Biomodels delivers actionable, data-driven insights that are essential for accelerating drug development pipelines. Their collaborative service model ensures that research protocols are meticulously aligned with the specific therapeutic goals of their partners, positioning the company as a vital link in the translational medicine value chain.
How much funding has Biomodels raised?
Biomodels has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Biomodels
PPP
Public-Private Partnership
What's next for Biomodels?
With the successful acquisition of this latest financing, Biomodels is well-positioned to scale its service offerings and enhance its technological capabilities in microbiome research and advanced surgical modeling. The strategic focus will likely shift toward optimizing laboratory throughput and expanding the firm's footprint in the competitive CRO landscape. By leveraging this capital, the organization aims to solidify its market leadership, ensuring that it remains at the forefront of preclinical innovation while meeting the increasing demand for high-quality, reproducible research data in the life sciences sector. Future growth trajectories will likely involve further investment in proprietary research platforms and the expansion of its global client engagement strategy.
See full Biomodels company page
